Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Waldenström macroglobulinaemia.

Rafael Fonseca1, Suzanne Hayman

  • 1Division of Hematology-Oncology, Mayo Clinic Scottsdale, Scottsdale, AZ, USA. fonseca.rafael@mayo.edu

British Journal of Haematology
|August 4, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.

American journal of hematology·2026
Same author

Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Clinical evaluation of ex vivo expanded MUC1-specific peripheral blood T Cells for adoptive immunotherapy in relapsed/refractory multiple myeloma.

Cancer research communications·2026
Same author

Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotype.

British journal of haematology·2026
Same author

A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.

Blood advances·2026
Same author

Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases.

Oncology and therapy·2026
Same journal

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma.

British journal of haematology·2026
Same journal

Immortal time bias limits the conclusion that post-transplant hypomethylating agent maintenance improves outcomes in myelodysplastic syndromes.

British journal of haematology·2026
Same journal

Author response to Zhang and Chen.

British journal of haematology·2026
Same journal

Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol.

British journal of haematology·2026
Same journal

Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.

British journal of haematology·2026
Same journal

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.

British journal of haematology·2026
See all related articles

Waldenström macroglobulinaemia (WM) is a distinct B-cell neoplasm defined by lymphoplasmacytic bone marrow infiltrate and IgM paraprotein. Treatment varies, with novel therapies under investigation for this rare cancer.

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Waldenström macroglobulinaemia (WM) has evolved from a clinical syndrome to a recognized clinicopathological entity.
  • The disease is characterized by lymphoplasmacytic bone marrow infiltration and monoclonal IgM paraprotein.
  • Symptoms arise from tumor infiltration and the rheological effects of IgM.

Purpose of the Study:

  • To review the current understanding and definition of Waldenström macroglobulinaemia.
  • To outline the diagnostic criteria and treatment approaches for WM.
  • To discuss emerging therapeutic strategies for WM.

Main Methods:

  • Review of the Second International Workshop on WM criteria.
  • Analysis of clinical manifestations and diagnostic features.

Related Experiment Videos

  • Summary of current and investigational treatment options.

    • Main Results:

    • WM is defined as a B-cell neoplasm with specific bone marrow findings and IgM paraprotein.
    • Treatment is reserved for symptomatic patients and lacks a universal standard.
    • Established treatments include rituximab, chemotherapy, and stem cell transplant; novel agents are being explored.

    Conclusions:

    • Standardization of WM definition and response criteria is progressing.
    • Treatment decisions for WM are individualized based on symptoms and patient eligibility.
    • Ongoing research into novel therapies holds promise for improving WM management.